The new generation of particle therapy focused on boron element (boron-neutron capture therapy: BNCT) -Steboronine, the world's first approved BNCT drug-

○Hideki Nakashima

Presentation information

Symposium

[S11] Developing the next generation small-molecule pharmaceuticals using a wide variety of elements

Sat. Mar 27, 2021 3:45 PM - 5:45 PM [Room D] Oral Presentation D (Online)

Organizer: Fujii Shinya (Inst. Biomaterials Bioengineering, Tokyo Med. Dent. Univ.), Ohta Kiminori (School of Pharmacy, Showa Univ.)

5:17 PM - 5:40 PM

[S11-6] The new generation of particle therapy focused on boron element (boron-neutron capture therapy: BNCT) -Steboronine, the world's first approved BNCT drug-

○Hideki Nakashima¹ (1. STELLA PHARMA SakaiRDC)

A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.

Presentation information

[S11] Developing the next generation small-molecule pharmaceuticals using a wide variety of elements

[S11-6] The new generation of particle therapy focused on boron element (boron-neutron capture therapy: BNCT) -Steboronine, the world's first approved BNCT drug-

Password